Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the representatives of the several underwriters in connection with the $201.25 million public offering by Pacific Biosciences of California, Inc. of 20,125,000 shares (which includes the exercise in full by the underwriters of their option to purchase up to 2,625,000 additional shares). The common stock is listed on the Nasdaq Global Select Market under the symbol “PACB”.
Based in Menlo Park, California, Pacific Biosciences is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye, Michelle Zhang and Ivey Eugene. The intellectual property and technology transactions team included partner David R. Bauer and associates Alison T. Chin and Francesca Masella. The tax team included partner Kara L. Mungovan and associates Benjamin Helfgott and Michelle Zhao. Counsel Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.